Brain Damage With Heart Failure: Cardiac Biomarker Alterations and Gray Matter Decline

Karsten Mueller1, Friederike Thiel1, Frank Beutner2,3

  • 1From the Max Planck Institute for Human Cognitive and Brain Sciences, Germany (K.M., F.T., S.F., T.B., H.E.M., K.I., A.V., M.L.S.).

Circulation Research
|January 24, 2020
PubMed

Insights

Heart failure (HF) is linked to brain structure changes. Reduced heart function correlates with decreased gray matter density (GMD) in key brain areas, suggesting potential cognitive implications.

Area of Science:

  • Cardiology
  • Neurology
  • Neuroimaging

Background:

  • Heart failure (HF) impairs cardiac function, reducing blood flow and potentially affecting brain oxygen supply.
  • Neurological symptoms are common in HF, but the underlying structural brain changes and their mechanisms are not fully understood.
  • Existing research suggests regional gray matter reduction in HF patients, necessitating further investigation into the heart-brain axis.

Purpose of the Study:

  • To investigate the relationship between cardiac function markers and structural brain changes in patients with heart failure.
  • To explore correlations between heart failure biomarkers and gray matter density (GMD) using magnetic resonance imaging (MRI).
  • To determine if impaired heart function is associated with specific alterations in brain structure.

Main Methods:

  • A case-control study was conducted with 80 patients from the Leipzig Heart Center.
  • Magnetic resonance imaging (MRI) was used to assess gray matter density (GMD) in the brain.
  • Key heart failure biomarkers, including ejection fraction and NT-proBNP (N-terminal prohormone of brain natriuretic peptide), were measured and correlated with GMD.

Main Results:

  • A significant positive correlation was observed between cardiac ejection fraction and GMD in the frontal and parietal medial cortex.
  • A significant negative correlation was found between NT-proBNP levels and GMD in the medial and posterior cingulate cortex, precuneus, and hippocampus.
  • Diminished GMD was associated with decreased ejection fraction and increased NT-proBNP, affecting widespread brain regions including the frontomedian cortex, hippocampus, and precuneus.

Conclusions:

  • Significant correlations exist between brain structure (GMD) and heart failure markers (ejection fraction, NT-proBNP).
  • Reduced heart function in HF is associated with diminished GMD in brain regions crucial for cognition, such as the hippocampus and precuneus.
  • These structural brain changes may underlie cognitive alterations in HF, warranting further longitudinal research to confirm causality.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
715
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
479
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
607
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
617
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K